BioPrism is a CMC-native AI platform that turns experimental data and manufacturing records into submission ready regulatory documents. Across the biopharma development lifecycle, BioPrism reduces months of manual compliance work to days.
Each one points to the same gap: documentation that isn't ready when the science is.
1FDA CRL release via openFDA, July 2025; analysis by Pharma Manufacturing.
2Industry analyses of public FDA IND clinical hold data.
3Industry benchmark; published CMC review timelines.
Source documents to submission-ready CMC sections. With traceability and review built in.
bioprism_flow.svg next to this HTML file (same folder), then reload. See browser console for details.
BioPrism shifts expert effort to where it matters. Authoring collapses. Review and judgment do not.
less time on CMC authoring. Experts focus on review and judgment, not first drafts.
Biopharma teams face structural changes in how regulatory documentation must be authored, exchanged, and validated. BioPrism is built for what comes next.
Emerging regulatory frameworks require structured, machine readable submissions. Legacy authoring tools cannot meet them.
More candidates, the same documentation headcount. CMC has become the gating function for clinical timelines.
Domain specific, controlled AI systems can now meet the audit and traceability standards regulators expect.
BioPrism is built by a team of CMC, regulatory, and AI/ML practitioners. The founding team brings 20+ years of regulatory and manufacturing experience across Merck, AstraZeneca, Spark Therapeutics, and Passage Bio, including active authorship of a gene therapy BLA currently under FDA review.
The technical foundation is built by senior machine learning engineers with two decades of large scale ML leadership at Amazon, Coinbase, Barclays, and JPMorgan. Domain depth is reinforced by senior CMC and analytical practitioners and a scientific advisory board with biologics and gene therapy expertise.
For biopharma teams across drug development